These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38765726)

  • 21. Review of treatment for alopecia totalis and alopecia universalis.
    Kassira S; Korta DZ; Chapman LW; Dann F
    Int J Dermatol; 2017 Aug; 56(8):801-810. PubMed ID: 28378336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multi-Concentration Level Patch Test Guided Diphenyl Cyclopropenone (DPCP) Treatment in Alopecia Totalis or Alopecia Universalis.
    Thuangtong R; Varothai S; Triwongwaranat D; Rujitharanawong C
    J Med Assoc Thai; 2017 Jan; 100(1):86-92. PubMed ID: 29911776
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is the severity of initial sensitization to diphenylcyclopropenone in alopecia areata patients predictive of the final clinical response?
    Ghandi N; Seifi G; Nasimi M; Abedini R; Mirabedian S; Etesami I; Ehsani A
    Dermatol Ther; 2021 Nov; 34(6):e15118. PubMed ID: 34464020
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata.
    Kennedy Crispin M; Ko JM; Craiglow BG; Li S; Shankar G; Urban JR; Chen JC; Cerise JE; Jabbari A; Winge MC; Marinkovich MP; Christiano AM; Oro AE; King BA
    JCI Insight; 2016 Sep; 1(15):e89776. PubMed ID: 27699252
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-Term Prognosis of Alopecia Totalis and Alopecia Universalis: A Longitudinal Study with More than 10 Years of Follow-Up: Better than Reported.
    Jang YH; Hong NS; Moon SY; Eun DH; Lee WK; Chi SG; Kim JY; Lee WJ; Lee SJ; Kim DW
    Dermatology; 2017; 233(2-3):250-256. PubMed ID: 28704810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of diphenylcyclopropenone among Chinese patients with steroid resistant and extensive alopecia areata.
    Luk NM; Chiu LS; Lee KC; Chau CT; Lee VW; Chang M; Lam YK; Lee HC
    J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):e400-5. PubMed ID: 23057682
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extensive alopecia areata: not necessarily recalcitrant to therapy!
    Deshpande D; Dhurat R; Saraogi P; Mishra S; Nayak C
    Int J Trichology; 2011 Jul; 3(2):80-3. PubMed ID: 22223966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is methotrexate an effective and safe treatment for maintaining hair regrowth in people with alopecia totalis? A Critically Appraised Topic.
    Browne R; Stewart L; Williams HC
    Br J Dermatol; 2018 Sep; 179(3):609-614. PubMed ID: 29777625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of chronic extensive alopecia areata by diphenylcyclopropenone alone versus in combination with anthralin.
    Ibrahim SA; Esawy AM; Abdelshafy AS
    Dermatol Ther; 2019 Sep; 32(5):e13010. PubMed ID: 31237076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
    Almutairi N; Nour TM; Hussain NH
    Dermatology; 2019; 235(2):130-136. PubMed ID: 30566941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diphenylcyclopropenone (diphencyprone, DPCP) in the treatment of chronic severe alopecia areata (AA).
    Galadari I; Rubaie S; Alkaabi J; Galadari H
    Eur Ann Allergy Clin Immunol; 2003 Dec; 35(10):397-401. PubMed ID: 14768526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diphenylcyclopropenone and platelet-rich plasma in the management of severe or recalcitrant alopecia areata.
    Abd El-Magid WM; Mohamed RA; Elsharkawy RE
    J Cosmet Dermatol; 2023 Nov; 22(11):2971-2981. PubMed ID: 37313640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum level of IL-4 predicts response to topical immunotherapy with diphenylcyclopropenone in alopecia areata.
    Gong Y; Zhao Y; Zhang X; Qi S; Li S; Ye Y; Yang J; Caulloo S; McElwee KJ; Zhang X
    Exp Dermatol; 2020 Mar; 29(3):231-238. PubMed ID: 30047620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subclinical sensitization with diphenylcyclopropenone is sufficient for the treatment of alopecia areata: Retrospective analysis of 159 cases.
    Choe SJ; Lee S; Pi LQ; Keum DI; Lee CH; Kim BJ; Lee WS
    J Am Acad Dermatol; 2018 Mar; 78(3):515-521.e4. PubMed ID: 29108907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A retrospective comparative study of the efficacy and safety of two regimens of diphenylcyclopropenone in the treatment of recalcitrant alopecia areata.
    Sriphojanart T; Khunkhet S; Suchonwanit P
    Dermatol Reports; 2017 Oct; 9(2):7399. PubMed ID: 29299216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complete Regrowth of Beard Hair with Ruxolitinib in an Alopecia Universalis Patient.
    Ramot Y; Zlotogorski A
    Skin Appendage Disord; 2018 Apr; 4(2):122-124. PubMed ID: 29765973
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Case report of novel combination of anthralin and calcipotriene leading to trichologic response in alopecia areata.
    Krueger L; Peterson E; Shapiro J; Lo Sicco K
    JAAD Case Rep; 2019 Mar; 5(3):258-260. PubMed ID: 30891474
    [No Abstract]   [Full Text] [Related]  

  • 38. Limited efficacy of diphenylcyclopropenone in the treatment of alopecia areata: Experience from a Tertiary Healthcare Institution in Singapore.
    Leong WMS; Mok ZR; Chandran NS
    Dermatol Ther; 2020 Nov; 33(6):e14447. PubMed ID: 33098604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic Impact of Home-Use versus Office-Use Diphenylcyclopropenone in Extensive Alopecia Areata.
    Lekhavat C; Rattanaumpawan P; Juengsamranphong I
    Skin Appendage Disord; 2022 Mar; 8(2):108-117. PubMed ID: 35419425
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.